Loading...

News List

超20亿美元!武田引进一款抗Aβ疫苗

2024-05-17


5月13日,武田宣布与AC Immune就针对Aβ的疫苗产品ACI-24.060达成了一项全球独家选择权和许可协议。ACI-24.060是一款抗Aβ免疫治疗候选药物,旨在诱导针对被认为是驱动斑块形成和阿尔茨海默病进展的毒性Aβ的强烈抗体应答。通过诱导斑块清除并有效抑制大脑中斑块形成,ACI-24.060有可能延缓阿尔茨海默病的进展

Pre: Astrazeneca's "first-in-class" oral small molecule is approved by the FDA

Next: Over $2 billion! Takeda introduces an anti-Aβ vaccine

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.